Terbinafine Tablet
Product Images NDC 69097-859

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Terbinafine (NDC 69097-859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (250mg 30tabs)

Terbinafine Tablets, USP 250 mg oral tablets label with a 30-tablet count. The label states the product is prescription only, manufactured by InvaGen Pharmaceuticals, a Cipla Ltd. subsidiary, and labeled for Cipla USA Inc. It includes storage instructions and a barcode.*

FDA Label Image

Image 2 (Terbinafine Str)

Chemical structure diagram of Terbinafine hydrochloride, showing the molecular arrangement of atoms and bonds in the compound.*

FDA Label Image

Image 1 (Terbinafine Table)

A data table comparing the percentage of adverse events and discontinuations between Terbinafine tablets and placebo groups. It covers symptoms including headache, gastrointestinal symptoms (diarrhea, dyspepsia, abdominal pain, nausea, flatulence), dermatological symptoms (rash, pruritus, urticaria), liver enzyme abnormalities, taste disturbance, and visual disturbance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.